156 related articles for article (PubMed ID: 24613163)
1. Design of antiviral stapled peptides containing a biphenyl cross-linker.
Muppidi A; Zhang H; Curreli F; Li N; Debnath AK; Lin Q
Bioorg Med Chem Lett; 2014 Apr; 24(7):1748-51. PubMed ID: 24613163
[TBL] [Abstract][Full Text] [Related]
2. Dual-acting stapled peptides target both HIV-1 entry and assembly.
Zhang H; Curreli F; Waheed AA; Mercredi PY; Mehta M; Bhargava P; Scacalossi D; Tong X; Lee S; Cooper A; Summers MF; Freed EO; Debnath AK
Retrovirology; 2013 Nov; 10():136. PubMed ID: 24237936
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.
Zhang H; Curreli F; Zhang X; Bhattacharya S; Waheed AA; Cooper A; Cowburn D; Freed EO; Debnath AK
Retrovirology; 2011 May; 8():28. PubMed ID: 21539734
[TBL] [Abstract][Full Text] [Related]
4. A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
Zhang H; Zhao Q; Bhattacharya S; Waheed AA; Tong X; Hong A; Heck S; Curreli F; Goger M; Cowburn D; Freed EO; Debnath AK
J Mol Biol; 2008 May; 378(3):565-80. PubMed ID: 18374356
[TBL] [Abstract][Full Text] [Related]
5. Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity.
Bocanegra R; Nevot M; Doménech R; López I; Abián O; Rodríguez-Huete A; Cavasotto CN; Velázquez-Campoy A; Gómez J; Martínez MÁ; Neira JL; Mateu MG
PLoS One; 2011; 6(9):e23877. PubMed ID: 21931621
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors.
Zhang X; Sun L; Meuser ME; Zalloum WA; Xu S; Huang T; Cherukupalli S; Jiang X; Ding X; Tao Y; Kang D; De Clercq E; Pannecouque C; Dick A; Cocklin S; Liu X; Zhan P
Eur J Med Chem; 2021 Dec; 226():113848. PubMed ID: 34592608
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Dual-acting Hydrocarbon-stapled Peptides against HIV-1 Predominantly Circulating in China.
Wang Y; Curreli F; Xu WS; Li ZP; Kong S; Ren L; Hong KX; Jiang SB; Shao YM; Debnath AK; Ma LY
Biomed Environ Sci; 2017 Jun; 30(6):398-406. PubMed ID: 28705263
[TBL] [Abstract][Full Text] [Related]
8. Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1.
Yang Y; Pannecouque C; Clercq E; Zhuang C; Chen FE
Bioorg Chem; 2020 Jun; 99():103825. PubMed ID: 32334191
[TBL] [Abstract][Full Text] [Related]
9. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor.
Liu W; An X; Wang J; Zhang X; Tan J; Zhou Z; Zeng Y
Bioorg Med Chem Lett; 2018 Mar; 28(5):910-914. PubMed ID: 29433929
[TBL] [Abstract][Full Text] [Related]
10. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly.
Kožíšek M; Štěpánek O; Parkan K; Berenguer Albiñana C; Pávová M; Weber J; Krӓusslich HG; Konvalinka J; Machara A
Bioorg Med Chem Lett; 2016 Aug; 26(15):3487-90. PubMed ID: 27353536
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of prodrug-type anti-HIV agents conjugating a REVERSE transcriptase inhibitor to a HIV-1 integrase inhibitor by a spontaneously cleavable linker.
Fossey C; Vu AH; Vidu A; Zarafu I; Laduree D; Schmidt S; Laumond G; Aubertin AM
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):591-607. PubMed ID: 18035828
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
14. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
15. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating, dimeric α-helical peptides: nanomolar inhibitors of HIV-1 transcription.
Jang S; Hyun S; Kim S; Lee S; Lee IS; Baba M; Lee Y; Yu J
Angew Chem Int Ed Engl; 2014 Sep; 53(38):10086-9. PubMed ID: 25056130
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity.
Curreli F; Belov DS; Ramesh RR; Patel N; Altieri A; Kurkin AV; Debnath AK
Bioorg Med Chem; 2016 Nov; 24(22):5988-6003. PubMed ID: 27707628
[TBL] [Abstract][Full Text] [Related]
19. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.
Gómara MJ; Galatola R; Gutiérrez A; Gimeno MC; Gatell JM; Sánchez-Merino V; Yuste E; Haro I
Curr Med Chem; 2014; 21(2):238-50. PubMed ID: 24083612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
